In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The firm presented data at the European Society for Medical Oncology Virtual Congress last weekend showing how its method could identify signs of early-stage cancers.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
Using proteomic, phosphoproteomic, and genomic data, researchers uncovered informative features in primary and metastatic samples from almost 150 CRC cases in China.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
